Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
BRIDGEWATER, N.J., April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first-quarter 2024 financial results on Thursday, May 9, 2024.
新澤西州布里奇沃特，2024年4月25日 /PRNewswire/ — 以改變嚴重和罕見疾病患者生活爲使命的全球生物製藥公司Insmed Incorporated（納斯達克股票代碼：INSM）今天宣佈，將於2024年5月9日星期四發佈2024年第一季度財務業績。
Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, May 9, 2024, to discuss the financial results and provide a business update.
Insmed管理層將於美國東部時間2024年5月9日星期四上午8點開始爲投資者舉行電話會議，討論財務業績並提供業務最新情況。
Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code 7862189. The call will also be webcast live on the Company's website at .
股東和其他利益相關方可以通過撥打（888）210-2654（美國）和（646）960-0278（國際）並引用接入代碼7862189來參加電話會議。電話會議還將在公司網站上進行網絡直播，網址爲 。
A replay of the conference call will be accessible approximately 1 hour after its completion through June 8, 2024, by dialing (800) 770-2030 (U.S.) and (609) 800-9909 (international) and referencing access code 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website at .
電話會議結束後約1小時即可觀看電話會議的重播，直至2024年6月8日，請撥打（800）770-2030（美國）和（609）800-9909（國際），參考接入代碼7862189。電話會議的網絡直播也將在公司網站的 “投資者關係” 部分存檔90天，網址爲 。
About Insmed
關於 Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan. Visit to learn more.
Insmed Incorporated是一家全球生物製藥公司，其使命是改變嚴重和罕見疾病患者的生活。Insmed的第一個商用產品是美國、歐洲和日本批准的首款用於治療慢性衰弱性肺部疾病的病中療法。該公司正在開發一系列強大的研究性療法，這些療法針對的是嚴重需求未得到滿足的領域，包括中性粒細胞介導的炎症性疾病和罕見的肺部疾病。Insmed還在推進涵蓋各種技術和模式的早期研究引擎，包括人工智能驅動的蛋白質工程、基因療法和蛋白質製造。Insmed總部位於新澤西州布里奇沃特，在美國、歐洲和日本設有其他辦事處和研究地點。訪問以了解更多信息。
Contact:
聯繫人：
Investors:
投資者：
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
[email protected]
布萊恩·鄧恩
投資者關係執行董事
Insmed
(646) 812-4030
[電子郵件保護]
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
[email protected]
埃莉諾·巴里瑟
投資者關係副董事
Insmed
(718) 594-5332
[電子郵件保護]
Media:
媒體：
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
[email protected]
Mandy Fahey
企業傳播執行董事
Insmed
(732) 718-3621
[電子郵件保護]
SOURCE Insmed Incorporated
來源 Insmed 公司
譯文內容由第三人軟體翻譯。